HC Wainwright Reiterates Buy Rating for MediWound (NASDAQ:MDWD)

HC Wainwright reaffirmed their buy rating on shares of MediWound (NASDAQ:MDWD) in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a $25.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for MediWound’s FY2029 earnings at $2.45 EPS.

Separately, Craig Hallum began coverage on MediWound in a research note on Friday, February 28th. They set a “buy” rating and a $39.00 price target for the company.

MediWound Stock Performance

Shares of NASDAQ MDWD opened at $16.27 on Thursday. The firm has a market capitalization of $175.60 million, a P/E ratio of -5.61 and a beta of 0.82. MediWound has a one year low of $12.78 and a one year high of $24.00. The company’s fifty day moving average is $18.17 and its two-hundred day moving average is $17.59.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.23. The business had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.79 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same quarter in the previous year, the company posted ($0.19) EPS. On average, sell-side analysts forecast that MediWound will post -2.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Investor AB acquired a new position in MediWound in the 3rd quarter valued at about $15,750,000. Yelin Lapidot Holdings Management Ltd. raised its stake in MediWound by 13.4% in the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company’s stock valued at $15,154,000 after purchasing an additional 100,618 shares during the last quarter. Essex Investment Management Co. LLC raised its stake in MediWound by 30.7% in the 4th quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company’s stock valued at $2,651,000 after purchasing an additional 35,012 shares during the last quarter. Northern Trust Corp raised its stake in MediWound by 94.6% in the 4th quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company’s stock valued at $2,577,000 after purchasing an additional 70,367 shares during the last quarter. Finally, Sargent Investment Group LLC raised its stake in MediWound by 3.4% in the 4th quarter. Sargent Investment Group LLC now owns 121,190 shares of the biopharmaceutical company’s stock valued at $2,217,000 after purchasing an additional 3,998 shares during the last quarter. Institutional investors and hedge funds own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.